SG11202010387QA - Starting dose of pth conjugates - Google Patents

Starting dose of pth conjugates

Info

Publication number
SG11202010387QA
SG11202010387QA SG11202010387QA SG11202010387QA SG11202010387QA SG 11202010387Q A SG11202010387Q A SG 11202010387QA SG 11202010387Q A SG11202010387Q A SG 11202010387QA SG 11202010387Q A SG11202010387Q A SG 11202010387QA SG 11202010387Q A SG11202010387Q A SG 11202010387QA
Authority
SG
Singapore
Prior art keywords
starting dose
pth
conjugates
pth conjugates
dose
Prior art date
Application number
SG11202010387QA
Other languages
English (en)
Inventor
Kennett Sprogøe
David Brian Karpf
Claus Strange
Original Assignee
Ascendis Pharma Bone Diseases As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascendis Pharma Bone Diseases As filed Critical Ascendis Pharma Bone Diseases As
Publication of SG11202010387QA publication Critical patent/SG11202010387QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11202010387QA 2018-05-18 2019-05-17 Starting dose of pth conjugates SG11202010387QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18173155 2018-05-18
PCT/EP2019/062773 WO2019219896A1 (fr) 2018-05-18 2019-05-17 Dose initiale de conjugués de la pth

Publications (1)

Publication Number Publication Date
SG11202010387QA true SG11202010387QA (en) 2020-11-27

Family

ID=62217789

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202010387QA SG11202010387QA (en) 2018-05-18 2019-05-17 Starting dose of pth conjugates

Country Status (11)

Country Link
US (1) US20210196801A1 (fr)
EP (1) EP3793587A1 (fr)
JP (1) JP2021524445A (fr)
KR (1) KR20210013584A (fr)
CN (1) CN112334152A (fr)
AU (1) AU2019270464A1 (fr)
BR (1) BR112020022306A2 (fr)
CA (1) CA3099620A1 (fr)
MX (1) MX2020012179A (fr)
SG (1) SG11202010387QA (fr)
WO (1) WO2019219896A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7059195B2 (ja) * 2016-03-01 2022-04-25 アセンディス ファーマ ボーン ディジージズ エー／エス Ｐｔｈプロドラッグ
KR20230170810A (ko) 2016-09-29 2023-12-19 아센디스 파마 본 디지즈 에이/에스 낮은 피크 대 트로프 비를 가진 pth 화합물
KR20240013849A (ko) 2016-09-29 2024-01-30 아센디스 파마 본 디지즈 에이/에스 조절 방출 pth 화합물을 위한 투여 용법
JP2023510790A (ja) * 2020-01-13 2023-03-15 アセンディス ファーマ ボーン ディジージズ エー／エス 副甲状腺機能低下症の治療
AU2021349316A1 (en) * 2020-09-28 2023-04-27 Ascendis Pharma Bone Diseases A/S Improvement of physical and mental well-being of patients with hypoparathyroidism

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US7332164B2 (en) 2003-03-21 2008-02-19 Enzon Pharmaceuticals, Inc. Heterobifunctional polymeric bioconjugates
JP4698579B2 (ja) 2003-04-08 2011-06-08 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 可逆的ｐｅｇ化薬物
US7690003B2 (en) 2003-08-29 2010-03-30 Fuller Jeffrey C System and method for increasing data throughput using thread scheduling
TW200526254A (en) 2003-09-19 2005-08-16 Novo Nordisk As Novel GLP-1 derivatives
ES2741524T3 (es) 2004-03-23 2020-02-11 Ascendis Pharma Gmbh Profármaco polimérico con un enlazador autoinmolador
US7244709B2 (en) * 2004-05-10 2007-07-17 Nastech Pharamecutical Company Inc. Compositions and methods for enhanced mucosal delivery of parathyroid hormone
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
MX2009002859A (es) 2006-09-15 2009-03-30 Enzon Pharmaceuticals Inc Enlazadores biodegradables a base de ester impedido para suministro de oligonucleotidos.
NZ580670A (en) 2007-06-21 2011-09-30 Univ Muenchen Tech Biological active proteins having increased in vivo and/or vitro stability
US20090016985A1 (en) 2007-07-11 2009-01-15 Enzon Pharmaceuticals, Inc. Polymeric drug delivery system containing a multi-substituted aromatic moiety
CN101980725B (zh) * 2008-02-01 2013-06-12 阿森迪斯药物股份有限公司 包含可自裂解的连接体的前药
EP2288261A4 (fr) 2008-05-23 2013-09-25 Enzon Pharmaceuticals Inc Systèmes polymères contenant un lieur disulfure intracellulaire libérable pour la délivrance d oligonucléotides
EP2393828B1 (fr) 2009-02-03 2016-10-12 Amunix Operating Inc. Polypeptides recombinants étendus et compositions les comprenant
US9173953B2 (en) 2009-07-31 2015-11-03 Ascendis Pharma As Prodrugs containing an aromatic amine connected by an amido bond to a linker
CN102724967A (zh) 2009-12-31 2012-10-10 安龙制药公司 包括可释放的脲连接体的含芳香胺化合物的聚合缀合物
WO2011089216A1 (fr) 2010-01-22 2011-07-28 Ascendis Pharma As Lieurs de précurseurs à base de dipeptides pour des médicaments contenant des amines aliphatiques
EP2525831B1 (fr) 2010-01-22 2019-05-15 Ascendis Pharma A/S Liens de promédicaments à base de carbamates liés à un support
EP2525829A1 (fr) 2010-01-22 2012-11-28 Ascendis Pharma A/S Lieurs de promédicaments à base de dipeptides pour des médicaments à teneur en amine aromatique
WO2011123813A2 (fr) 2010-04-02 2011-10-06 Amunix Operating Inc. Protéines de fusion liantes, conjugués protéines de fusion liantes-médicaments, conjugués xten-médicaments et procédés pour les préparer et les utiliser
JP5977229B2 (ja) 2010-05-05 2016-08-24 プロリンクス リミテッド ライアビリティ カンパニー 巨大分子共役体からの徐放
JP5964815B2 (ja) 2010-05-05 2016-08-03 プロリンクス リミテッド ライアビリティ カンパニー 固体担体からの放出制御薬物
SI2571510T1 (sl) 2010-05-21 2019-02-28 Xl-Protein Gmbh Biosintetični prolin/alaninski naključno zviti polipeptidi in njihove uporabe
CN102959585B (zh) 2010-06-30 2016-03-30 日本电气方案创新株式会社 属性确定方法、属性确定装置及属性确定系统
AU2012296954B2 (en) 2011-08-12 2016-09-15 Ascendis Pharma A/S Carrier-linked treprostinil prodrugs
EP3643306A3 (fr) 2011-08-12 2020-08-26 Ascendis Pharma A/S Promédicaments liés à un support dotés de liaisons ester carboxylique réversibles
CA2843503C (fr) 2011-08-12 2020-12-22 Ulrich Hersel Promedicaments lies a des excipients polymeriques hyperbranches
EP2741782B1 (fr) 2011-08-12 2020-05-06 Ascendis Pharma A/S Prodrogues liés à un support protéinique
WO2013036857A1 (fr) 2011-09-07 2013-03-14 Prolynx Llc Coupleurs au sulfone
US20150087688A1 (en) 2012-04-25 2015-03-26 Ascendis Pharma A/S Prodrugs of hydroxyl-comprising drugs
JP2015536314A (ja) 2012-10-17 2015-12-21 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 成長ホルモン送達のための脂肪酸アシル化アミノ酸
AU2015299055C1 (en) 2014-08-06 2021-05-06 Ascendis Pharma A/S Prodrugs comprising an aminoalkyl glycine linker
JP7059195B2 (ja) * 2016-03-01 2022-04-25 アセンディス ファーマ ボーン ディジージズ エー／エス Ｐｔｈプロドラッグ
KR20240013849A (ko) * 2016-09-29 2024-01-30 아센디스 파마 본 디지즈 에이/에스 조절 방출 pth 화합물을 위한 투여 용법
WO2018060311A1 (fr) * 2016-09-29 2018-04-05 Ascendis Pharma Bone Diseases A/S Schéma posologique incrémentiel dans des composés de pth à libération contrôlée

Also Published As

Publication number Publication date
AU2019270464A1 (en) 2020-11-19
MX2020012179A (es) 2021-01-29
EP3793587A1 (fr) 2021-03-24
BR112020022306A2 (pt) 2021-02-23
JP2021524445A (ja) 2021-09-13
CA3099620A1 (fr) 2019-11-21
KR20210013584A (ko) 2021-02-04
WO2019219896A1 (fr) 2019-11-21
US20210196801A1 (en) 2021-07-01
CN112334152A (zh) 2021-02-05

Similar Documents

Publication Publication Date Title
IL272410A (en) Cytokine conjugates for the treatment of autoimmune diseases
SG11202010387QA (en) Starting dose of pth conjugates
IL264674B1 (en) Antibodies to siglec7 for cancer treatment
GB201804255D0 (en) Macrophage-based therapy
IL282330A (en) therapeutic compounds
IL284047A (en) Combined treatment of HBV
GB201819853D0 (en) Therapy
GB201716942D0 (en) Therapeutic compounds
SG11202008718UA (en) Combination therapy for cardiovascular diseases
GB201615439D0 (en) Dose setting mechanism
PL3655079T3 (pl) Jednodawkowy inhalator proszkowy
IL276996A (en) inhaler
GB201808150D0 (en) Therapeutic compounds
ZA201907286B (en) A pharmaceutical combination for the treatment of a cancer
PL3630754T3 (pl) Związki izoindolinoacetylenowe do leczenia nowotworu
EP3801713C0 (fr) Inhalateur
GB2569410B (en) Booster burner
GB201817385D0 (en) Therapy
GB201814038D0 (en) Ilven therapy
GB201712884D0 (en) Novel therapeutic compounds
GB201809828D0 (en) Combined hormal therapy
GB201814652D0 (en) Tube capsule etc
GB201712388D0 (en) Therapeutic compounds
GB201712390D0 (en) Therapeutic compounds
GB201712392D0 (en) Therapeutic compounds